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Summary
Pterin-4a-carbinolamine dehydratase (PCD) is required
for efficient tetrahydrobiopterin regeneration after phe-
nylalanine hydroxylase activity. This catalytic function
was proposed to be specifically defective in newborns
with a mild form of hyperphenylalaninemia (HPA) and
persistent high urinary levels of primapterin (7-biop-
terin). A second regulatory task of the same protein is
DCoH, a coactivation of transcription by hepatocyte
nuclear factor 1a (HNF-1a), a function that is appar-
ently not impaired in these HPA individuals. It has been
shown elsewhere that the human PCD/DCoH bifunc-
tional protein is encoded by a single 4-exon–containing
gene, PCBD, located on chromosome 10q22. We have
now examined the PCBD gene for mutations at the ge-
nomic level in six such HPA patients from four different
families. By the use of new intron-specific primers, we
detected, in all six patients, single, homozygous nucle-
otide alterations, in exon 4, that were inherited from
their parents. These homozygous alterations predicted
mutant PCD/DCoH with a single amino acid exchange,
in two cases (alleles T78I), or premature stop codons,
in the other four patients (alleles E86X and Q97X). Re-
combinant expression in Escherichia coli revealed that
the mutant proteins—T78I, E86X, and Q97X—are al-
most entirely in the insoluble fraction, in contrast towild
type, which is expressed as a soluble protein. These data
support the proposal that HPA in combination with uri-
nary primapterin may be due to autosomal recessive in-
heritance of mutations in the PCBD gene specifically
affecting the dehydratase activity.
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Introduction
Hyperphenylalaninemias (HPAs) are routinely diag-
nosed by the elevated plasma phenylalanine (Phe) con-
centration but need subsequent urinary pterin analysis,
in newborns, to differentiate between various types of
underlying molecular defects. The variants of HPA in
which Phe hydroxylase per se is not affected are gen-
erally more severe, since they all originate from a defect
in the synthesis or regeneration of tetrahydrobiopterin
(BH4), the obligatory Phe hydroxylase cofactor. BH4 is
furthermore required for the first step of dopamine and
serotonin neurotransmitter biosyntheses carried out by
tyrosine hydroxylase and tryptophan hydroxylase
(Scriver et al. 1994, 1995). The three aromatic amino
acid hydroxylases need the reduced cofactor to activate
molecular oxygen and hydroxylate the corresponding
amino acids (Kaufman 1993). During this enzymatic re-
action, 4a-hydroxy-tetrahydrobiopterin is released and
BH4 is regenerated, in two enzymatic steps. The first step
is dehydration to quinonoid-dihydrobiopterin by pterin-
4a-carbinolamine dehydratase (PCD) (Lazarus et al.
1983). In the next step, dihydropteridine reductase re-
cycles the cofactor to BH4 in an NADH-dependent re-
action (Whiteley et al. 1993). The reduced cofactor is
endogenously supplied by de novo biosynthesis from
GTP catalyzed by the enzymes GTP cyclohydrolase I, 6-
pyruvoyl-tetrahydropterin synthase (PTPS), and sepiap-
terin reductase. Sufficient BH4 cofactor regeneration and
de novo biosynthesis appear to be essential for control-
ling plasma Phe concentration and monoamine neuro-
transmitter production.
The known defects in BH4 metabolism include lesions
in two biosynthetic enzymes, GTP cyclohydrolase I and
PTPS, and in at least one cofactor-regenerating enzyme,
dihydropteridine reductase (Blau et al. 1993). Autoso-
mal recessive mutations in all the corresponding genes
have been identified and correlate with persistent HPA
and, at least for the severe types of defects, with neu-
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rotransmitter deficiency (Smooker and Cotton 1995;
Tho¨ny and Blau 1997).
More recently, a new and apparently rare form of
transient HPA was described with plasma Phe concen-
trations ranging from very high to moderately elevated
(Blaskovics and Giudici 1988; Dhondt et al. 1988).
Pterin analysis of this type of HPA is characterized by
persistently elevated levels of urinary 7-biopterin (prim-
apterin; Blau et al. 1989; Adler et al. 1992). This pterin
derivative was shown to arise, at least under in vitro
conditions, from nonenzymatic rearrangement of 4a-hy-
droxy-tetrahydropterin in the absence of PCD (Curtius
et al. 1990; Davis et al. 1991). In agreement with this
proposal, a patient was described who carried com-
pound heterozygous mutations in the PCBD gene, en-
coding the corresponding mutant PCD proteins with re-
duced dehydratase activity (Citron et al. 1993; Johnen
et al. 1995; Ko¨ster et al. 1995b). The conclusion that
rapid dehydration by the homotetrameric PCD in the
BH4 recycling pathway is essential to prevent formation
of primapterin, under a Phe load, substantiated the pro-
posal that this new form of HPA might be due to reduced
dehydratase activity (Bailey et al. 1993; Ko¨ster et al.
1995b, 1996; Rebrin et al. 1995).
Although the proposal that PCD activity is directly
affected in such HPA patients appears rational, it is con-
founded by the recognition that the same “dehydratase”
polypeptide has a second function, that of DCoH (Men-
del et al. 1991; Citron et al. 1992; Hansen and Crabtree
1993; Hauer et al. 1993; Tho¨ny et al. 1993). DCoH
forms a heterotetrameric complex with the nuclear tran-
scription factor hepatocyte nuclear factor 1a (HNF-1a)
and thereby stimulates HNF-1a–dependent gene ex-
pression. However, there is no evidence for any dimin-
ished activity of HNF-1a–dependent gene expression in
primapterinuric patients. Moreover, direct in vivo data
are not available thus far, either for reduced enzymatic
PCD activity in HPA patients or for the significance of
transcriptional coactivation by DCoH.
A further complication arises from the proposal that
the observed reduction of PCD/DCoH dehydratase ac-
tivity and subsequent accumulation of primapterin is
responsible for depigmentation in melanocytes of pa-
tients with the skin disorder vitiligo (Schallreuter et al.
1994a, 1994b). In contrast to the skin depigmentation,
such vitiligous patients have not been observed to suffer
from HPA.
The gene for this multifunctional protein, PCBD, is
located on human chromosome 10q22 and is expressed
from a single, 4-exon–containing transcript, from which
the 103–amino-acid active PCD/DCoH is encoded by
exons 2–4 only (Citron et al. 1993; Hauer et al. 1993;
Tho¨ny et al. 1994a, 1995). The knowledge of the exact
intron-exon structure has allowed us to examine the cod-
ing region for PCD/DCoH for mutations. To further test
the proposal that primapterinuric patients have a ge-
netically based defect in their PCD, we analyzed six in-
dividuals with HPA and high urinary primapterin, from
four different families. The results presented here show
that there are functional alterations in the corresponding
gene from all patients. The association of HPA and uri-
nary primapterin with mutations in the PCBD gene in
all such patients corroborates the hypothesis that they
are specifically defective in dehydratase.
Patients and Methods
Case Reports
Patients reported herein are registered in the BIODEF
database (Blau et al. 1997). All are from nonconsan-
guineous parents and were identified on the basis of their
high plasma Phe in neonatal screening tests.
Patient K.A. (BIODEF 264) is the first child of Cau-
casian parents. The initial Guthrie test, performed at age
3 d, showed a plasma Phe level of 290 mmol/liter; the
recall specimen showed a level of 853 mmol/liter at 6 d
and 1,997 mmol/liter at 13 d. Introduction of Lofenalac
normalized the plasma Phe levels to 157 mmol/liter after
7 d. Initial screening for urinary pterins indicated a high
neopterin/biopterin ratio and increased levels of prim-
apterin (table 1). A repeat specimen, obtained at age 1
mo, showed a pattern of neopterin and biopterin being
essentially normal but with persistent primapterinuria.
Neurological examination of patient K.A. at age 6 d
identified no abnormalities. A second evaluation at age
1 mo showed mild hypotonia of the extremities and
trunk. At age 2.5 years, the Phe diet was stopped, and
patient K.A. subsequently developed completely
normally.
Patient J.S. (BIODEF 211) is the second child of His-
panic parents. Primapterinuria was diagnosed at age 8
d through a neonatal screening program (Blaskovics and
Giudici 1988) (table 1). The patient’s plasma Phe levels
increased from 399 mmol/liter at age 1 d to 756 mmol/
liter at age 28 d. An oral BH4–loading test lowered the
plasma Phe concentrations to normal levels. Following
oral BH4 administration (2 mg/kg/d), neopterin nor-
malized, and biopterin as well as primapterin increased
about eight-fold (Blau et al. 1989). A similar effect was
obtained after administration of dihydrobiopterin (6 mg/
kg) and sepiapterin (3 mg/kg) (Blau et al. 1992). The
restriction of Phe intake was replaced by administration
of BH4 (2 mg/kg/d) for the first 8 mo of life. The only
clinical manifestations of neurological impairment be-
fore introduction of BH4 were transient abnormality on
electroencephalogram and progressive hypotonia with a
delay in motor development. Hyperphenylalaninemia
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Table 1
HPLC Analysis of Urinary Pterins
Patient Age
Neopterin
(mmol/mol creatinine)
Biopterin
(mmol/mol creatinine)
Primapterin
(mmol/mol creatinine) %Biopterina %Primapterinb
K.A. 18 d 10.90 .48 .22 4.2 31.4
1 mo 1.10 .80 .14 42.1 14.9
J.S. 8 d 16.74 .41 .39 2.4 48.8
1 mo 7.84 .38 .30 4.6 44.1
7 moc 3.32 2.18 2.59 39.6 54.3
3 years 4.23 1.04 .90 19.7 46.4
T.S. 1.5 years 1.57 .60 .51 27.6 45.9
4 years 3.20 1.12 .59 25.9 34.5
4 yearsd 2.41 2.89 1.34 54.5 31.7
I.B. 10 mo 1.90 4.80 1.60 71.6 25.0
14 mo 1.40 .63 .77 31.0 55.0
J.B. 2 years 1.20 1.90 2.30 61.3 54.8
B.E. 3 mo 3.70 .37 1.09 9.1 74.7
Controls !4 years 1.1–4.0 .5–3.0 !.02 44–77 NA
a %Biopterin  100# biopterin/(neopterin  biopterin).
b %Primapterin  100# primapterin/(primapterin  biopterin). NA  not applicable.
c On BH4 (2.5 mg/kg/d).
d After dihydrobiopterin loading (100 mg).
was transient, although the pterin pattern remained con-
stant with increasing age (table 1). Patient J.S. is now
8.5 years old and, on an ordinary diet, is developing
normally. A sibling, patient T.S. (BIODEF 212), who is
1.5 years older than patient J.S., showed a similar uri-
nary pterin pattern (table 1), had a transient plasma Phe
elevation in the neonatal period, and is now clinically
normal (Giudici et al. 1991).
Patient I.B. (BIODEF 273) was born at term to parents
of Ashkenazi Jewish origin. Newborn screening at age
3 d showed plasma Phe at 240 mmol/liter. Repeated
measurements on day 14 showed plasma Phe levels of
1,845 mmol/liter. On a low-Phe diet (38 mg/kg/d), the
patient’s plasma Phe level fell rapidly to a normal level
over a period of 36 h. Patient I.B. has a high tolerance
for Phe of ∼80–90 mg (Arn et al. 1994). The patient’s
pterin profile in urine at age 2 wk showed 1.8% of
biopterin (E. Naylor, personal communication), sug-
gesting PTPS deficiency. Dihydropteridine reductase ac-
tivity was normal. Repeated plasma and urine measure-
ment at age 3 wk showed, again, an elevated
neopterin-to-biopterin ratio. An oral BH4–loading test
(10 mg/kg body weight) resulted in a decrease of plasma
Phe from 540 mmol/liter to 234 mmol/liter and then to
196 mmol/liter within 4 and 8 h, respectively. At age 1
mo, pterin and neurotransmitters in the cerebrospinal
fluid (CSF) were normal, suggesting a peripheral biop-
terin deficiency (K. Hyland, personal communication).
The patient was put on a Phe-restricted diet, together
with administration of BH4 (5 mg/kg/d).
We reevaluated patient I.B. at age 2 mo and found a
normal PTPS activity in the red blood cells of the patient;
of his sister, patient J.B. (BIODEF 344); and of both
parents. The urinary pterin profile, during BH4 treat-
ment, showed normal neopterin and biopterin but in-
creased primapterin (table 1), indicating a deficiency of
PCD. The patient was treated with an unrestricted diet
and oral BH4 (10 mg/kg/d) for 4 mo. After 4 mo, BH4
was discontinued, and Phe levels, which were 120–300
mmol/liter, are still within this range at age 5 years. Both
patient I.B. and his sister, patient J.B., who has the same
genotype, are developing normally. Neither child is on
pharmacological treatment or a restricted diet. Hyper-
phenylalaninemia was never documented in the 18-mo-
older sibling.
Patient B.E. (BIODEF 272) is the second child of un-
related parents. Pregnancy and delivery were normal.
Birth weight was 2.9 kg. At the initial neonatal screen
at age 3 d, plasma Phe was 183 mmol/liter. This is below
the “normal” cut-off of 240 mmol/liter, so instead of the
usual follow-up, a repeat neonatal screen was done at
3 wk, at which time plasma Phe was found to be 1,600
mmol/liter. The child was immediately brought to the
clinic center. The peak Phe level, at 3.5 wk, was 2,589
mmol/liter. The child was started on a low-Phe formula,
and levels were stabilized, mostly !400 mmol/liter. He
was observed to have considerable Phe tolerance (∼100
mg/kg). The initial urinary pterin profile (F. Moyhuddin,
personal communication) showed an increased neop-
terin-to-biopterin ratio of 15, indicating a defect in the
biosynthesis of BH4. A BH4-loading test (6 mg/kg) at age
6 wk showed only a slight response (Phe at 0 h, 731
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Table 2
Oligonucleotides for PCBD-Exon Amplifications and for DNA
Sequence Analysis Using Intronic Primers
Exon
Sense
Primer
Antisense
Primer
Product
Size
(bp)
Sequencing
Primer
2 PCDH60 PCDH23 413 PCDH60
3 PCDH62 PCDH61 538 PCDH73
4 PCDH64 PCDH63 721 PCDH74
NOTE.—Primer sequences: PCDH23: 5′-(7637) AAG ACA CAT
CCT CCT ATG GC (7618)-3′; PCDH60: 5′-(7225) TGG AGC CCC
TCT GTT TTG AC (7244)-3′; PCDH61: 5′-(8246) AGG GGT ATT
TAT GTT GAT TC (8227)-3′; PCDH62: 5′-(7709) TGA AGA CAT
TTG AAC AGA CG (7728)-3′; PCDH63: 5′-(9720) GAG CCT GAG
ACC AAG TGA TA (9701)-3′; PCDH64: 5′-(9000) AGG GGA GAT
GTA GAA GAT GT (9019)-3′; PCDH73: 5′-(7899) TTC ATC CTC
CTG CGT CTA (7916)-3′; PCDH74: 5′-(9112) GTG ACT CCC TCC
TGT TCT T (9130)-3′. The nucleotide numbers given in parentheses
refer to the published PCBD gene sequence (GenBank accession num-
ber L41560; Tho¨ny et al. 1995).
mmol/liter; at 3 h, 612 mmol/liter; and at 6 h, 502 mmol/
liter). A week later, at a BH4 dose of 22 mg/kg, there
was a definite response (Phe at 0 h, 773 mmol/liter; at 3
h, 517 mmol/liter; and at 6 h, 155 mmol/liter). CSF neu-
rotransmitter concentrations were normal, suggesting a
peripheral deficiency (K. Hyland, personal communi-
cation). Reevaluation at age 3 mo established the di-
agnosis of primapterinuria. We found normal PTPS ac-
tivity in the red blood cells of patient B.E., of his sister,
and of both parents. Percentage of urinary biopterin was
rather low, and increased concentrations of primapterin
were found (table 1). He was initially treated with 25
mg BH4 daily. This was discontinued, at age 4 mo, with
no change in Phe levels; since then, Phe levels have re-
mained stable, at 100–250 mmol/liter, on an unrestricted
normal diet. Clinical assessment at age 3.5 years dem-
onstrated normal growth and development. The patient
was noted to have prominent epicanthic folds and in-
creased carrying angles at the elbows but no other dys-
morphic features.
HPLC Analysis of Urinary Pterins and CSF Metabolites
BH4 was purchased from Dr. Schircks’s laboratory in
Jona, Switzerland. HPLC of pterins, after oxidation with
manganese dioxide, was performed as described else-
where (Curtius et al. 1991).
Genomic DNA Analysis by Exon-Specific Amplification
and Direct Sequencing of PCR Products
Genomic DNA was isolated from blood leukocytes by
means of standard extraction procedures (Sambrook et
al. 1989). Oligonucleotides for PCR and for sequencing
were synthesized on a Gene Assembler Plus DNA syn-
thesizer (Pharmacia Biotech) and are compiled in table
2. Conditions for PCR amplification were as follows: 1
mg genomic DNA was incubated in a 40-ml PCR reaction
containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl,
0.1% Triton X-100, 200 mM dNTP, 40 pmol of each
primer, 0.8 U Taq polymerase (Promega), and either 1.5
mM MgCl2, for exon 2, or 3 mM MgCl2, for exons 3
and 4. Amplification was carried out in a Perkin-Elmer
Cetus DNA thermocycler for 35 cycles, with denatur-
ation at 95C for 1 min, annealing at 62C for 1 min,
and extension at 72C for 1 min. A final extension step
at 72C for 7 min was added. PCR products were sep-
arated on a 1% agarose gel and purified by use of a
Qiagen Gel Extraction Kit. Sequencing was performed
in accordance with a procedure described elsewhere
(Tho¨ny et al. 1994b).
Recombinant Expression of Mutant PCD/DCoH
An Escherichia coli plasmid vector expressing the
T87I-PCD/DCoH recombinant mutant protein was gen-
erated by two consecutive PCR amplifications, basically
as described elsewhere, using the 5′ and 3′ primers
PCDH15 (5′-CGG AAT TCA TAT GGC TGG CAA
AGC ACA CAG-3′) and PCDH16 (5′-CGG GAT CCT
ATG TCA TGG ACA CTG CTA C-3′) and the mutagenic
primer PCDH80 (5′-TCA CGC TGA GCA TCC ATG
AGT GTG C-3′) (Ko¨ster et al. 1995a, 1995b). The
PCDH15 primer contains two consecutive recognition
sequences for the enzymes EcoRI and NdeI, and primer
PCDH16 harbors a BamHI site. After amplification and
restriction-enzyme digestion, the EcoRI/BamHI frag-
ment was subcloned into pUC18 (plasmid pHDH65).
Subsequently, the NdeI/BamHI fragment was isolated
from pHDH65 and inserted into pGEMEX-2-Nde to
yield plasmid pHDH66. Plasmid constructs for the trun-
cated mutants E86X- and Q97X-PCD/DCoH were gen-
erated in a similar way. Fragments were directly ampli-
fied from the wild-type cDNA template by use of the 5′
primer PCDH15 in combination with either PCDH76
(5′-CGG GAT CCT TAT GAA AGG CCG GCA CAC
TCT A-3′), for mutant E86X, or PCDH77 (5′-CGG GAT
CCT TAT TCG ATG AAG CTG GCC AGG T-3′), for
mutant Q97X. This yielded the pUC18 derivatives
pHDH60 (E86X) and pHDH61 (Q97X) and the cor-
responding pGEMEX-2-Nde plasmid derivatives
pHDH63, for mutant E86X-PCD, and pHDH64, for
Q97X-PCD. Expression was achieved from the p-
GEMEX-2-Nde derivatives by standard isopropyl b-D-
thio-galactopyranoside induction, for 3 h, of
logarithmically growing cultures of E. coli BL21(DE3)
(Promega). Cells were harvested by centrifugation, re-
suspended in 5 mM Tris-HCl, pH 8.0, 40 ml/liter of
cells, and fast frozen.
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Table 3
Mutation Analysis of the PCBD Gene from Six HPA Patients with 7-Biopterins
FAMILY AND/OR
INDIVIDUAL (STATUS)
BASE-PAIR CHANGEa
AMINO ACID
CHANGEbExon 2 Exon 3 Exon 4
K.A. (male, patient) wt wt 312CrT/312CrT Q97X homozygous
Family S:
H.S. (mother) wt wt 256CrT/wt T78I heterozygous
J.S. (daughter, patient) wt wt 256CrT/256CrT T78I homozygous
T.S. (son, patient) wt wt 256CrT/256CrT T78I homozygous
Family B:
S.B. (father) wt wt 279GrT/wt E86X heterozygous
A.B. (mother) wt wt 279GrT/wt E86X heterozygous
I.B. (son, patient) wt wt 279GrT/279GrT E86X homozygous
J.B. (daughter, patient) wt wt 279GrT/279GrT E86X homozygous
Family E:
R.E. (father) wt wt 312CrT/wt Q97X heterozygous
D.C. (mother) wt wt 312CrT/wt Q97X heterozygous
B.E. (son, patient) wt wt 312CrT/312CrT Q97X homozygous
a wt  wild-type sequence.
b X  termination codon. Since the N-terminal methionine is cleaved from the recombinant
dehydratase as well as from the enzyme isolated from human and rat liver, methionine is not
included in the numbering of the amino acid residues (Hauer et al. 1993; Ko¨ster et al. 1995a;
Ayling et al. 1997).
Extraction of Mutant Dehydratases
Cells containing mutant dehydratases were lysed ei-
ther by sonication or by freeze/thawing. In the first
method, the cell paste was thawed and sonicated, in 5-
ml aliquots, with a Branson Sonifier 250 set at 6. Son-
ication was carried out on ice, for three cycles of 15 s
each, with 1 min cooling between each cycle. In the
second method, the cell paste was thawed, rapidly re-
frozen in liquid nitrogen, and quickly thawed twice
more. The latter method of extraction was found to be
advantageous for measuring low levels of dehydratase
activity in crude extracts. The lysates were centrifuged
at 100,000 g for 60 min at 4C, and the supernatants
were frozen in liquid nitrogen and stored at 80C. In
all cases, samples of the lysates were removed before
centrifugation and were saved for SDS-PAGE analysis.
SDS-PAGE was performed by means of a procedure op-
timized for the separation of low–molecular-weight pro-
teins (Scha¨gger and von Jagow 1987), with 10% acryl-
amide in the separating gel.
Dehydratase-Activity Assay
Enzyme activity was measured by use of chemically
synthesized 4a-hydroxy-tetrahydropterins (Bailey et al.
1993, 1995), as described elsewhere (Bailey et al. 1993;
Rebrin et al. 1995). Activities were measured at 10C in
10 mM Tris-HCl, pH 8.2, in the presence of an excess
of dihydropteridine reductase (5 units/ml reaction) and
NADH (0.1 mM), with 6(S)-propyl-4a-hydroxy-tetra-
hydropterin (20 mM) as substrate. At this temperature,
buffer concentration, and pH, nonenzymatic dehydra-
tion of substrate is minimized. Reactions were monitored
at 340 nm until completed, and data were acquired by
computer. The first-order rate constant for nonenzymatic
dehydration was measured separately and entered as a
constant in fitting data to the rate equation. Maximum
velocities and Michaelis constants were calculated from
the rate equation for the complete progress curve by use
of the PC-compatible nonlinear regression program “Sci-
entist” (Micromath), as detailed elsewhere (Rebrin et al.
1995).
Results
Mutations in the PCBD Gene from HPA Patients with
Primapterinuria
The mature 103-residue PCD/DCoH protein mono-
mer is encoded by exons 2–4 of the human PCBD gene
(Citron et al. 1993; Tho¨ny et al. 1995). We thus estab-
lished PCR conditions to amplify these three exons from
genomic DNA from patients (table 2), and we examined
the coding sequences and flanking splice sites by direct
nucleotide-sequence determination. We analyzed six
HPA patients with primapterinuria, including family
members when available (table 3). Whereas no muta-
tions were detected in exons 2 and 3, all patients ex-
hibited, homozygously, single-nucleotide alterations in
exon 4 that originated from the corresponding parents.
Tho¨ny et al.: Hyperphenylalaninemia Due to PCD Deficiency 1307
Moreover, the mutations predicted an amino acid
exchange or premature termination codons (see fig. 1).
A mutant allele, Q97X, an exchange from Gln97 to a
termination codon, was detected in patient K.A. (fig. 1A)
and, in family E, in patient B.E. (fig. 1D). In family S,
patients T.S. and J.S. had a mutation predicting a ho-
mozygous Thr78rIle alteration (allele T78I; fig. 1B).
The two patients I.B. and J.B., from family B, had an
exchange from Glu86 to a termination codon (allele
E86X; fig. 1C).
Expression of Mutant Dehydratases
To investigate the effect of alterations in sequence on
protein function, we expressed these mutant dehydra-
tases in E. coli. In all cases, the wild-type recombinant
dehydratase, which has properties identical to those of
the human liver enzyme (Ayling et al. 1997), was run
as a control. Analysis by SDS-PAGE showed that all of
the wild-type dehydratase is in the soluble fraction
(100,000 g supernatant), where typically one-third of
the soluble protein is dehydratase. SDS-PAGE analysis
of the 100,000 g supernatants of each of the mutants
revealed only negligible amounts of protein at the de-
hydratase position. On the other hand, when solubilized
whole-cell lysates were analyzed by SDS-PAGE, the
amount of mutant protein corresponding to dehydratase
was similar to that obtained with wild type. Thus, it
appears that, although soluble and functional wild-type
dehydratase can be expressed in E. coli, almost all of
the mutant protein is in an inactive, insoluble form.
Catalytic Activity of Mutant Dehydratases
Since only a small fraction of the mutant dehydratase
was in the soluble fraction, the cell extracts were ana-
lyzed for catalytic activity without further protein pu-
rification. The 100,000 g supernatants were concen-
trated in a Centricon 30 (Amicon), washed with
enzyme-assay buffer, and concentrated again. Surpris-
ingly, the extracts of the truncation mutants, Q97X and
E86X, contained activity, although at low levels. In an
attempt to increase the amount of these proteins in the
soluble fraction, E. coli containing the mutant dehydra-
tases were grown at 20C. This resulted in a 10-fold
increase in E86X and a 4-fold increase in Q97X activity
in the soluble fraction, compared with the activities of
the extracts from cells grown at 37C. The Michaelis
constant (Km) of 6-propyl-4a-hydroxy-tetrahydropterin
with E86X appeared to be similar to that of wild type,
whereas with Q97X, the Km was two to three times
higher. Since the amounts of Q97X and E86X mutant
proteins in the soluble fractions were insufficient to en-
able purification, turnover values for these mutants
could not be determined. No activity could be detected
in the T78I extract, which indicates either that there was
insufficient dehydratase protein in the soluble fraction
or that the dehydratase in the soluble fraction has very
low or no activity. Attempts to obtain any T78I activity
in the soluble fraction were without success, which in-
dicates either that the dehydratase in this fraction had
very low or no activity or that insufficient dehydratase
protein was solubilized.
Discussion
Primapterin has been shown to arise from rearrange-
ment of 4a-hydroxy-BH4, the substrate of PCD. It was
therefore postulated that primapterinuria may be due to
a defect in the dehydratase (PCD). Through analysis of
the dehydratase gene of six patients with transient HPA
and persistent urinary primapterin, we found that all
have homozygous alterations and that the parents were
heterozygous for the mutation. Therefore, this defect ap-
pears to be an autosomal recessive trait (MIM 264070).
In addition to the six patients reported here, another
patient with similar symptoms was found to have com-
pound heterozygous mutations in the PCBD gene (Cit-
ron et al. 1993). Moreover, five more patients currently
being characterized all show mutations in exons 2, 3,
or 4 of the PCBD gene (Blau et al. 1997; Tho¨ny et al.,
in press).
With the information about the site and type of codon
alteration, it would be of interest to determine whether
there is any correlation between genotype and pheno-
type. However, the severity of a mutation such as, for
example, the truncated E86X allele appears not to lead
to a specifically higher percentage of urinary primapterin
when compared among the different patients. Moreover,
the identical mutant allele Q97X homozygously present
in two patients gave rise to 14.9% primapterin at age
1 mo for patient K.A. and 74.7% primapterin at age 4
mo for patient B.E. (table 1). Thus, the variability in the
amount of urinary primapterin (or plasma Phe) appears,
at least with the available data, not to be correlated to
the observed mutations.
The functional consequences of the predicted amino
acid alterations for dehydratase activity were analyzed.
When wild-type human dehydratase is expressed in E.
coli, all of the dehydratase is found in the soluble frac-
tion, even when expression levels of the dehydratase are
as high as 35% of the soluble protein. The enzyme can
be extracted and purified in 190% yield and is fully
active, with catalytic parameters indistinguishable from
those of enzyme isolated from rat or human liver (Ayling
et al. 1997). Under identical conditions of expression,
essentially all of the dehydratase of the mutants T78I,
E86X, and Q97X was in the insoluble fraction. How-
ever, at least with E86X and Q97X, the small amount
of dehydratase in the soluble fraction was sufficient to
show that both of these mutants do have some catalytic
Figure 1 Sequence analysis and detection of mutations in exon 4 of the PCBD gene in HPA patients. A, Patient K.A. B, Family S. C, Family B. D, Family E. Direct nucleotide-sequence
determination of PCR products was performed as described in Patients and Methods. Arrowheads mark the site of base alterations detected. The coding triplets and corresponding amino acids,
numbered according to the PCD/DCoH-cDNA, are indicated (Tho¨ny et al. 1995).
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activity and that both retain the ability to bind substrate
with a Km, which does not differ significantly from wild
type. The E86X truncated mutant even lacks the com-
plete C-terminal a3-helix. Thus, although the a3-helix
contributes to catalytic activity, it is not absolutely es-
sential. Whether the inability to detect any catalytic ac-
tivity with T78I is due to its being totally insoluble, or
totally inactive, will require expression in another system
with less propensity to package recombinant proteins
into insoluble forms. A recombinant system that retains
a higher percentage of the expressed protein in the sol-
uble fraction will also allow E86X and Q97X to be
purified and the specific catalytic activities of these two
mutants to be compared to the catalytic activity of wild-
type dehydratase.
The observation that each of the three mutant dehy-
dratases is found primarily in the insoluble fraction when
expressed in E. coli, even though all the wild type is in
the soluble fraction, reveals that the mutations have a
significant effect on the folding of the protein. This sug-
gests that, in vivo, these proteins may not fold correctly
or may fold sufficiently slowly that they are susceptible
to proteolysis.
All these data together support the hypothesis that
this benign form of HPA with high urinary levels of
primapterin is caused by recessive mutations in the
pterin-4a-carbinolamine dehydratase gene. Although the
PCBD mutations may result in mild HPA and excretion
of high levels of primapterin, no symptoms indicating
defective DCoH function have been observed so far.
Studies of the binding of dehydratase/DCoH to HNF-
1a and the effect on its transcriptional activity have been
performed, in vitro and in vivo, with several synthetic
mutants of DCoH (Johnen and Kaufman 1997; Sourdive
et al. 1997). So far, these studies have revealed that en-
zymatic activity and binding to HNF-1a are not nec-
essarily correlated. Nevertheless, the mutations found in
the patients reported here that may render the dehydra-
tase more susceptible to incorrect folding or to prote-
olysis have yet to be investigated for their effects on the
proposed DCoH function. The binding of these mutant
PCDs to HNF-1a and the consequences for HNF-1a
transcriptional activation are topics for future
investigation.
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